A Phase 2 interventional study of BI 409306 and Placebo in Schizophrenia, sponsored by Boehringer Ingelheim. Terminated at 59 sites in 7 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Schizophrenia by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Schizophrenia · Boehringer Ingelheim.
Among the 11 studies in Schizophrenia by Boehringer Ingelheim, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 2, and was the 5th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →None of the 11 studies in Schizophrenia by Boehringer Ingelheim is open now. The open studies under Schizophrenia, anywhere →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 264 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 509 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Schizophrenia by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who have experienced at least 2 relapses within the past 5 years or at least 1 relapse if they were diagnosed less than 3 years ago. Relapse is defined as the patient having any of the following using the above number of relapses and time frames:
Male or female patients.
-- Female patients of must be ready and able to use highly effective methods of per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. Patients must agree to use birth control throughout the trial and for at least 28 days after treatment has ended. Acceptable methods of birth control include combined estrogen-progestin oral, intravaginal or transdermal contraceptives, progestogen-only oral, injectable or implantable contraceptives, intrauterine devices (IUDs), intrauterine hormone releasing systems (IUSs), bilateral tubal occlusion, vasectomized sexual partner, and complete sexual abstinence (if acceptable by local health authorities) is allowed when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptom-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 film-coated tablet of 50 milligrams (mg) of BI 409306 plus 1 tablet of 25 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
Drug: BI 409306
1 film-coated tablet of 25 milligrams (mg) of BI 409306 plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
Drug: BI 409306
1 film-coated tablet of 25 milligrams (mg) of matching Placebo plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
Drug: Placebo
28 week treatment period
28 week treatment period
Incidence Rate of First Relapse After 28 Weeks of Treatment
The incidence rate of first relapse after 28 weeks of treatment is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.
Time frame: 28 weeks
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment
Positive and Negative Syndrome Scale (PANSS): assesses the severity of psychotic symptoms and progression of disease. The PANSS positive symptoms score is the sum of scores from 7 Items where each item has a minimum score 1 (better outcome) and maximum score 7 (worse outcome). The PANSS positive symptoms score ranges from 7 (less severe the disease) to 49 (more severe the disease).
Time frame: At baseline and at Week 28.
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment
Clinical Global Impressions-Severity (CGI-S): One-item evaluation completed by the clinician to measure the severity of psychopathology. The CGI-S score ranges from 1 (normal) through to 7 (most severely ill). The higher the score, the worse the psychopathology.
Time frame: At baseline and at Week 28
Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment
Patient Global Impressions-Improvement (PGI-I): One-item evaluation completed by the patient to assess their overall evaluation of his/her status compared to how they felt at randomisation. The PGI-I score ranges from 1 (Very much better) through to 7 (Very much worse). The higher the score, the worse the improvement.
Time frame: At Week 28
Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment
Columbia Suicide Severity Rating Scale (C-SSRS): suicide risk assessment. At a minimum, the interview consists of 2 screening questions related to suicidal ideation and 4 related to suicidal behavior, and may be expanded to up to 17 items in case of positive responses. Free text entries are allowed. Suicidal behavior is collected in nominal scale as presence/absence of actual attempts, non-suicidal self-injurious behavior, interrupted attempts, aborted attempts, preparatory acts or behavior, and any suicidal behavior. Suicidal ideation is rated on a 6-point scale from 0 (No ideation present) to 5 (Active ideation with plan and intent). A score of 4 or 5 on this scale indicates serious suicidal ideation. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.
Time frame: 28 weeks
Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment
Personal and Social Performance scale (PSP): The PSP is a 100-point, single item, clinician rated scale to assess 4 domains of social functioning (Four domains over the past month: (1) socially useful activities, (2) personal and social relationships, (3) self-care and (4) disturbing and aggressive behaviors.) in patients with schizophrenia. The PSP score is a single score ranging from 1 to 100. Higher scores represent better personal and social functioning.
Time frame: At baseline and at Week 28
Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication
The incidence rate of new prescription or increase in dose of an ongoing antipsychotic medication is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.
Time frame: 28 weeks
This Phase II trial aimed to evaluate the impact of 28-week treatment with BI 409306 (added to standard antipsychotic medication) compared with placebo on preventing relapse in patients with schizophrenia.
| Milestone | BI 409306 25 mg | BI 409306 50 mg | Placebo |
|---|---|---|---|
| Started | 89 | 88 | 87 |
| Completed | 62 | 48 | 53 |
| Not completed | 27 | 40 | 34 |
| Withdrew: Adverse event | 7 | 11 | 12 |
| Withdrew: Investigator's decision | 0 | 0 | 2 |
| Withdrew: System error | 0 | 0 | 2 |
| Withdrew: Covid-19 restrictions | 3 | 0 | 1 |
| Withdrew: Non-compliance | 2 | 5 | 0 |
| Withdrew: Withdrawal by subject | 11 | 16 | 13 |
| Withdrew: Lost to follow-up | 2 | 6 | 4 |
| Withdrew: Protocol violation | 2 | 2 | 0 |
The incidence rate of first relapse after 28 weeks of treatment is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.
| Events per patient-years | BI 409306 25 mg | BI 409306 50 mg | BI 409306 Pooled | Placebo |
|---|---|---|---|---|
| Incidence Rate of First Relapse After 28 Weeks of Treatment | 0.527 | 0.434 | 0.482 | 0.496 |
Positive and Negative Syndrome Scale (PANSS): assesses the severity of psychotic symptoms and progression of disease. The PANSS positive symptoms score is the sum of scores from 7 Items where each item has a minimum score 1 (better outcome) and maximum score 7 (worse outcome). The PANSS positive symptoms score ranges from 7 (less severe the disease) to 49 (more severe the disease).
| Score on a scale | BI 409306 25 mg | BI 409306 50 mg | BI 409306 Pooled | Placebo |
|---|---|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment | -0.54 (-1.370 to 0.294) | -0.71 (-1.641 to 0.224) | -0.61 (-1.231 to 0.005) | -0.92 (-1.769 to -0.070) |
Clinical Global Impressions-Severity (CGI-S): One-item evaluation completed by the clinician to measure the severity of psychopathology. The CGI-S score ranges from 1 (normal) through to 7 (most severely ill). The higher the score, the worse the psychopathology.
| Score on a scale | BI 409306 25 mg | BI 409306 50 mg | BI 409306 Pooled | Placebo |
|---|---|---|---|---|
| Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment | -0.15 ± 0.758 | -0.22 ± 0.839 | -0.18 ± 0.791 | -0.22 ± 0.718 |
Patient Global Impressions-Improvement (PGI-I): One-item evaluation completed by the patient to assess their overall evaluation of his/her status compared to how they felt at randomisation. The PGI-I score ranges from 1 (Very much better) through to 7 (Very much worse). The higher the score, the worse the improvement.
| Score on a scale | BI 409306 25 mg | BI 409306 50 mg | BI 409306 Pooled | Placebo |
|---|---|---|---|---|
| Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment | 2.61 ± 1.328 | 2.96 ± 1.197 | 2.76 ± 1.280 | 2.94 ± 1.190 |
Columbia Suicide Severity Rating Scale (C-SSRS): suicide risk assessment. At a minimum, the interview consists of 2 screening questions related to suicidal ideation and 4 related to suicidal behavior, and may be expanded to up to 17 items in case of positive responses. Free text entries are allowed. Suicidal behavior is collected in nominal scale as presence/absence of actual attempts, non-suicidal self-injurious behavior, interrupted attempts, aborted attempts, preparatory acts or behavior, and any suicidal behavior. Suicidal ideation is rated on a 6-point scale from 0 (No ideation present) to 5 (Active ideation with plan and intent). A score of 4 or 5 on this scale indicates serious suicidal ideation. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.
| Events per patient-years | BI 409306 25 mg | BI 409306 50 mg | BI 409306 Pooled | Placebo |
|---|---|---|---|---|
| Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment | 0.070 | 0.077 | 0.073 | 0.071 |
Personal and Social Performance scale (PSP): The PSP is a 100-point, single item, clinician rated scale to assess 4 domains of social functioning (Four domains over the past month: (1) socially useful activities, (2) personal and social relationships, (3) self-care and (4) disturbing and aggressive behaviors.) in patients with schizophrenia. The PSP score is a single score ranging from 1 to 100. Higher scores represent better personal and social functioning.
| Score on a scale | BI 409306 25 mg | BI 409306 50 mg | BI 409306 Pooled | Placebo |
|---|---|---|---|---|
| Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment | 2.8 ± 8.8 | 2.4 ± 9.4 | 2.6 ± 9.1 | 3.0 ± 10.2 |
The incidence rate of new prescription or increase in dose of an ongoing antipsychotic medication is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.
| Events per patient-years | BI 409306 25 mg | BI 409306 50 mg | BI 409306 Pooled | Placebo |
|---|---|---|---|---|
| Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication | 0.168 | 0.130 | 0.149 | 0.217 |
Collected over All-cause mortality: From first dose until withdraw or end of 1-week taper period + 3-week follow-up period, up to 32 weeks. Serious (non-serious) adverse events: From first dose until withdraw or end of 1-week taper period + 1-week residual effect period, up to 30 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BI 409306 25 mg | 0/89 (0%) | 9/89 (10.1%) | 30/89 (33.7%) |
| BI 409306 50 mg | 1/88 (1.1%) | 7/88 (8%) | 25/88 (28.4%) |
| Placebo | 0/87 (0%) | 12/87 (13.8%) | 19/87 (21.8%) |
| Total | 1/264 (0.4%) | 28/264 (10.6%) | 74/264 (28%) |
| Event | BI 409306 25 mg | BI 409306 50 mg | Placebo | Total |
|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 2/89 | 1/88 | 4/87 | 7/264 |
| PneumoniaInfections and infestations | 0/89 | 0/88 | 3/87 | 3/264 |
| Suicidal ideationPsychiatric disorders | 3/89 | 0/88 | 2/87 | 5/264 |
| IleusGastrointestinal disorders | 0/89 | 0/88 | 1/87 | 1/264 |
| Wound infectionInfections and infestations | 0/89 | 0/88 | 1/87 | 1/264 |
| Skin abrasionInjury, poisoning and procedural complications | 0/89 | 0/88 | 1/87 | 1/264 |
| AgitationPsychiatric disorders | 0/89 | 0/88 | 1/87 | 1/264 |
| DelusionPsychiatric disorders | 0/89 | 0/88 | 1/87 | 1/264 |
| Depression suicidalPsychiatric disorders | 0/89 | 0/88 | 1/87 | 1/264 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/89 | 0/88 | 1/87 | 1/264 |
| Event | BI 409306 25 mg | BI 409306 50 mg | Placebo | Total |
|---|---|---|---|---|
| PhotophobiaEye disorders | 3/89 | 8/88 | 1/87 | 12/264 |
| NasopharyngitisInfections and infestations | 7/89 | 5/88 | 7/87 | 19/264 |
| HeadacheNervous system disorders | 6/89 | 7/88 | 4/87 | 17/264 |
| InsomniaPsychiatric disorders | 5/89 | 6/88 | 0/87 | 11/264 |
| SchizophreniaPsychiatric disorders | 6/89 | 4/88 | 2/87 | 12/264 |
| VomitingGastrointestinal disorders | 1/89 | 1/88 | 5/87 | 7/264 |
| SomnolenceNervous system disorders | 5/89 | 3/88 | 3/87 | 11/264 |
Treated set (TS): the TS includes all patients who were randomised and were documented to have taken at least 1 dose of trial drug.
| Age, Continuous(Years) | BI 409306 25 mg | BI 409306 50 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 38.4 ± 9.8 | 41.9 ± 9.6 | 40.5 ± 9.8 | 40.3 ± 9.8 |
| Sex: Female, Male(Participants) | BI 409306 25 mg | BI 409306 50 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 29 | 36 | 32 | 97 |
| Male | 60 | 52 | 55 | 167 |
| Ethnicity (NIH/OMB)(Participants) | BI 409306 25 mg | BI 409306 50 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 15 | 15 | 40 |
| Not Hispanic or Latino | 75 | 69 | 68 | 212 |
| Unknown or Not Reported | 4 | 4 | 4 | 12 |
| Race (NIH/OMB)(Participants) | BI 409306 25 mg | BI 409306 50 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 23 | 20 | 20 | 63 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 0 | 2 |
| Black or African American | 36 | 37 | 32 | 105 |
| White | 23 | 24 | 25 | 72 |
| More than one race | 1 | 1 | 2 | 4 |
| Unknown or Not Reported | 6 | 4 | 8 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Data sharing details ↗ · www.mystudywindow.com
Ran from Dec 2017 to primary completion in Mar 2021, 39 months.
Results were first posted in Apr 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BI 409306